Table 1.

Combined efficacy: all patients in WELL401 and 401.10.001

OverdoseEarly-onsetOverall
Total enrolled11718135
Survivala114 (97%)16 (89%)130 (96%)
Death3 (3%)2 (11%)5 (4%)
  • aSurvival includes patients who survived at 30 days or patients who resumed chemotherapy prior to 30 days.